Not a traditional drug phase: Hemorrhoidal artery embolization for Internal Hemorrhoids
Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue.
Official registry: https://clinicaltrials.gov/study/NCT07179601 · University of California, Los Angeles · enrollment listed as 22
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Hemorrhoidal artery embolization. The registry lists allocation as na. Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids.
They plan to enroll about 22 people at Los Angeles. Taking part typically means a procedure as part of the study plus check-ins.
Official title (unrewritten)
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
Interventions: Hemorrhoidal artery embolization
Primary outcome (registry wording): Proportion of patients with decrease in bleeding related symptoms of internal hemorrhoids as defined as a two-point decrease in French Bleeding Score
Who it is for (from inclusion criteria)
- Ages 18 Years to 90 Years
- Symptomatic hemorrhoidal disease with French Bleeding Score (FBS) of at least four out of nine
- Refusal of or contraindication to surgery
- Refusal of or contraindication to other minimally invasive hemorrhoid treatments
- Grade I to III hemorrhoids
- Previous anoscopy or colonoscopy demonstrating internal hemorrhoids within 1 year
- Supply of the CCR from either the SRA or MRA on intra-procedural angiogram prior to embolization
Who the registry excludes
- Asymptomatic patients
- Patients who ever had previous colorectal surgery
- Grade IV hemorrhoids
- Colorectal disease other than hemorrhoids that could result in bleeding
- Anatomic findings on CTA that would preclude successful embolization
- Contraindication to iodinated contrast
- Active infection or malignancy
Public study contact (from the registry)
Renato Escobar
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- University of California, Los Angeles — Los Angeles, California (recruiting)
FAQ about this NCT record
Is NCT07179601 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07179601?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07179601?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary